Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Any ideas as when this share will be on the rise, considering what's happening? Any help greatly appreciated.
Just wondering? New successful vaccines methods - will there be a spin off? And will these new methods result in new vaccines for diseases which previously had no successful treatments or vaccines?? What does anyone think?
Some might not think much of Motley fool, but I picked OO out as good investment. And still hold.
Perhaps these organisations will come to Hvivo for their expertise.
What is uncrossing trade??? Why have gold sales dropped?? Newby.
I meant imutex!
Has anyone an idea when Imutex will be sold or is it going on the NEW YORK STOCK EXCHANGE?
As you are on the call, can you ask cf why he thinks this share has gone down - especially after the government contract?
Can't make the call myself.
Why have gold sales dropped at Centamin? And how long before production goes up again - any ideas? Just asking your opinion.
We're On the BBC NEWS and international news broadcasters. Great publicity for Challenge studies and hVivo!
Even NIAS are thinking about challenge studies.
Dr. Arthur Caplan, a bioethicist and professor at NYU Langone Health, told Yahoo Finance that back in March, many drug companies were against the idea, saying such trials would be too risky. But that’s changing now. In addition, NIAID recently revealed it has been preparing for the possibility of running a challenge trial.
And even with several vaccines in late stages of clinical trials, the remainder of the more than 180 candidates globally are likely to benefit if a human challenge trial is used.
Caplan, who is on the advisory board of 1DaySooner, which has advocated for such trials and has thousands of petitioners who say they would sign up for one, said it still makes sense to pursue, because “we still don’t know if the first round of vaccines will work.”
hVivo’s Catchpole said the challenge trial “can really expedite judging the efficacy of a vaccine in a safe and informative way.”
A traditional clinical trial stops when a certain number of infected individuals is reached — and if a majority of those infected are in a placebo group, the vaccine is considered a success. But it also depends on participants’ habits and locations — if they are in a hotspot or are roaming around in the middle of one intentionally trying to expose themselves, versus if they are in the middle of a low-incidence area or are following safety protocols.
Catchpole said that since the company announced it intentions in March, it began working on the strategy and protocols with experts. In addition, hVivo is working closely with the U.K. government.
Cathal Friel, hVivo’s executive chairperson, told Yahoo Finance that in addition to the U.K. launch, the company is also in final stages for establishing a quarantine center in Australia, and “shortly thereafter, in North America.” But where on the continent has yet to be revealed. In both cases, hVivo would be partnering, rather than running, the trials.
The??? Is why has it had its heart ripped out?
What will be takeover target open orphan or Hvyo?
Volunteers plenty of volunteers and they will be paid for it.
Good comments!
Because they need to get everything ready and get the volunteers, which I'm sure there will be plenty of. Also there is need of more than one vaccine to test to get an effective vaccine.
There are more than a hundred Covid vaccines being developed around the world and several front-runners already in the final stages of testing, including one from Oxford University.
Deputy chief medical officer Prof Jonathan Van-Tam said: "For the many vaccines still in the mid-stages of development, human challenge studies may help pick out the most promising ones to take forward into larger Phase 3 trials.
"For vaccines which are in the late stages of development and already proven to be safe and effective through Phase 3 studies, human challenge studies could help us further understand if the vaccines prevent transmission as well as preventing illness."
The first stage of the project will be delivered by a partnership between Imperial College London, the Royal Free Hospital's specialist and secure research unit in London and a company called hVIVO.
Volunteers will be monitored for up to a year after taking part in the study to check for any side-effects.
People can sign up for trials here.
Researchers are set to explore a human challenge study with the virus that causes COVID-19, the first such study anywhere in the world.
The Human Challenge Programme is a partnership between Imperial College London, the Department for Business, Energy and Industrial Strategy (BEIS), hVIVO, a leading clinical company with expertise in viral human challenge models, and the Royal Free London NHS Foundation Trust.
The researchers hope that the work will ultimately help to reduce the spread of the coronavirus, mitigate its impact and reduce deaths from COVID-19.
The first stage of the project will explore the feasibility of exposing healthy volunteers to the SARS-CoV-2 coronavirus. The study would recruit volunteers between the ages of 18 and 30 with no previous history or symptoms of COVID-19, no underlying health conditions and no known adverse risk factors for COVID-19, such as heart disease, diabetes or obesity.
Notice the comments says VACINNES, NOT JUST VACCINE!
accelerating the development of our most promising vaccines which will ultimately help in beginning our return to normal life."
Cathal Friel, Executive Chairman, Open Orphan, said:
"At Open Orphan we are pleased to be working on behalf of the UK Government and in partnership with two great institutions, Imperial College London and The Royal Free Hospital. We look forward to working with our partners to develop a COVID-19 human challenge study model which will be used to safely accelerate the discovery of effective vaccines and antivirals against COVID-19.
"We hope our work will reduce the impact of COVID-19 on individuals and communities, and our thoughts go out to the many people whose lives have been affected by the pandemic."
Alok Sharma, Business Secretary, UK Government, said:
"We are doing everything we can to fight coronavirus, including backing our best and brightest scientists and researchers in their hunt for a safe and effective vaccine.
"The funding announced today for these ground-breaking but carefully controlled studies marks an important next step in building on our understanding of the virus and accelerating the development of our most promising vaccines which will ultimately help in beginning our return to normal life."
Conference call for sell-side analysts and investors
The Company will hold a conference call for sell-side analysts and investors at 11:00 Thursday 22nd of October. Details for the conference call can be found at: https://www.speakservecloud.com/register-for-call/ecd1cd54-503e-4be0-8f00-3d0a0f92b6a1